ASCO GI 2023 | The role of TKIs in the management of hepatocellular carcinoma

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, comments on the role of tyrosine kinase inhibitors (TKIs) in treating hepatocellular carcinoma (HCC). Whilst checkpoint inhibitors have proven to be efficacious, TKIs are often used in the second line setting, and more research is required to elucidate the optimal regimen of TKIs. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.